<?xml version='1.0' encoding='utf-8'?>
<document id="25929522"><sentence text="The effects of drugs with immunosuppressive or immunomodulatory activities on xenobiotics-metabolizing enzymes expression in primary human hepatocytes." /><sentence text="In this paper we investigated the effects of several drugs used in transplant medicine, i" /><sentence text="e" /><sentence text=" cyclosporine A, tacrolimus, rapamycin, everolimus, mycophenolate mofetil, fluvastatin and rosuvastatin, on the expression of major drug-metabolizing enzymes in human hepatocytes"><entity charOffset="1-15" id="DDI-PubMed.25929522.s4.e0" text="cyclosporine A" /><entity charOffset="17-27" id="DDI-PubMed.25929522.s4.e1" text="tacrolimus" /><entity charOffset="29-38" id="DDI-PubMed.25929522.s4.e2" text="rapamycin" /><entity charOffset="40-50" id="DDI-PubMed.25929522.s4.e3" text="everolimus" /><entity charOffset="52-73" id="DDI-PubMed.25929522.s4.e4" text="mycophenolate mofetil" /><entity charOffset="75-86" id="DDI-PubMed.25929522.s4.e5" text="fluvastatin" /><entity charOffset="91-103" id="DDI-PubMed.25929522.s4.e6" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e0" e2="DDI-PubMed.25929522.s4.e6" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e1" e2="DDI-PubMed.25929522.s4.e6" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e2" e2="DDI-PubMed.25929522.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e2" e2="DDI-PubMed.25929522.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e2" e2="DDI-PubMed.25929522.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e2" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e2" e2="DDI-PubMed.25929522.s4.e6" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e3" e2="DDI-PubMed.25929522.s4.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e3" e2="DDI-PubMed.25929522.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e3" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e3" e2="DDI-PubMed.25929522.s4.e6" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e4" e2="DDI-PubMed.25929522.s4.e4" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e4" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e4" e2="DDI-PubMed.25929522.s4.e6" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e5" e2="DDI-PubMed.25929522.s4.e5" /><pair ddi="false" e1="DDI-PubMed.25929522.s4.e5" e2="DDI-PubMed.25929522.s4.e6" /></sentence><sentence text=" Moreover, we tested the ability of these drugs to affect transcriptional activity of glucocorticoid (GR) and aryl hydrocarbon receptor (AhR)"><entity charOffset="86-100" id="DDI-PubMed.25929522.s5.e0" text="glucocorticoid" /><entity charOffset="102-104" id="DDI-PubMed.25929522.s5.e1" text="GR" /><entity charOffset="110-126" id="DDI-PubMed.25929522.s5.e2" text="aryl hydrocarbon" /><pair ddi="false" e1="DDI-PubMed.25929522.s5.e0" e2="DDI-PubMed.25929522.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25929522.s5.e0" e2="DDI-PubMed.25929522.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s5.e0" e2="DDI-PubMed.25929522.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s5.e1" e2="DDI-PubMed.25929522.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s5.e1" e2="DDI-PubMed.25929522.s5.e2" /></sentence><sentence text=" We found that most of tested compounds did not induce expression of CYP1A1/1A2/3A4/2A6/2B6/2C9 mRNAs in human hepatocytes" /><sentence text=" Slight induction was observed for CYP2A6/2C9 mRNAs and CYP2A6 protein in the rapamycin-treated hepatocytes"><entity charOffset="78-87" id="DDI-PubMed.25929522.s7.e0" text="rapamycin" /></sentence><sentence text=" Decrease of CYP2A6 and CYP2B6 proteins was observed in rosuvastatin-treated cells"><entity charOffset="56-68" id="DDI-PubMed.25929522.s8.e0" text="rosuvastatin" /></sentence><sentence text=" Mycophenolate mofetil antagonized the effects of dexamethasone on GR but it potentiated the action of dioxin on AhR"><entity charOffset="1-22" id="DDI-PubMed.25929522.s9.e0" text="Mycophenolate mofetil" /><entity charOffset="50-63" id="DDI-PubMed.25929522.s9.e1" text="dexamethasone" /><entity charOffset="103-109" id="DDI-PubMed.25929522.s9.e2" text="dioxin" /><entity charOffset="67-72" id="DDI-PubMed.25929522.s9.e3" text="GR" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e0" e2="DDI-PubMed.25929522.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e0" e2="DDI-PubMed.25929522.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e0" e2="DDI-PubMed.25929522.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e0" e2="DDI-PubMed.25929522.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e1" e2="DDI-PubMed.25929522.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e1" e2="DDI-PubMed.25929522.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e1" e2="DDI-PubMed.25929522.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e3" e2="DDI-PubMed.25929522.s9.e3" /><pair ddi="false" e1="DDI-PubMed.25929522.s9.e3" e2="DDI-PubMed.25929522.s9.e2" /></sentence><sentence text=" Induction of CYP1A1 mRNA in HepG2 cells by dioxin was modestly antagonized by mycophenolate mofetil, while the induction by benzo[a]pyren or S-omeprazole was significantly potentiated by this drug"><entity charOffset="79-100" id="DDI-PubMed.25929522.s10.e0" text="mycophenolate mofetil" /><entity charOffset="125-138" id="DDI-PubMed.25929522.s10.e1" text="benzo[a]pyren" /><entity charOffset="142-154" id="DDI-PubMed.25929522.s10.e2" text="S-omeprazole" /><pair ddi="false" e1="DDI-PubMed.25929522.s10.e0" e2="DDI-PubMed.25929522.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25929522.s10.e0" e2="DDI-PubMed.25929522.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s10.e0" e2="DDI-PubMed.25929522.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25929522.s10.e1" e2="DDI-PubMed.25929522.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25929522.s10.e1" e2="DDI-PubMed.25929522.s10.e2" /></sentence><sentence text=" In general, tested compounds can be considered safe in the terms of possible drug-drug interaction caused by induction of drug-metabolizing cytochromes P450" /><sentence text=" Nevertheless, mycophenolate mofetil is of possible concern and its combination with drugs, environmental pollutants or food constituents, which activate AhR, may represent a significant toxicological risk"><entity charOffset="15-36" id="DDI-PubMed.25929522.s12.e0" text="mycophenolate mofetil" /></sentence><sentence text=" " /></document>